irinotecan has been researched along with Brain Edema in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Golby, AJ; McDannold, N; Power, C; Reardon, DA; Sun, T; Supko, JG; Vykhodtseva, N; Zhang, Y | 1 |
| Hu, T; Li, Q; Liu, C; Ma, Y; Wu, G; Xiong, J; Zhao, Y | 1 |
2 other study(ies) available for irinotecan and Brain Edema
| Article | Year |
|---|---|
Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Edema; Brain Neoplasms; Female; Glioma; Irinotecan; Magnetic Resonance Imaging; Male; Microbubbles; Pilot Projects; Prodrugs; Purpura; Random Allocation; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Sonication; Topoisomerase I Inhibitors | 2020 |
Apatinib + CPT-11 + S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer: Case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Edema; Brain Neoplasms; Camptothecin; Disease Progression; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Oxonic Acid; Pyridines; Tegafur; Triple Negative Breast Neoplasms | 2018 |